IP Library Granted Patent US 8,710,076
Granted Patent B2
US 8,710,076 · App. 13/124,901 · Granted Apr 29, 2014

2,5-disubstituted piperidine orexin receptor antagonists

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,710,076
App. No.
13/124,901
Granted
Apr 29, 2014
Kind
B2
Abstract

The present invention is directed to 2,5-disubstituted piperidine amide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

Claims (103)

1. A compound of the formula Ia:

wherein:

B is isoquinoline;

R 1a , R 1b and R 1c are independently selected from the group consisting of:

(1) hydrogen,

(2) halogen,

(3) C 1-6 alkyl,

(4) triazolyl,

(5) oxazolyl,

(6) pyrimidinyl, and

(7) phenyl;

R 2a , R 2b and R 2c are independently selected from the group consisting of:

(1) hydrogen,

(2) halogen,

(3) C 1-6 alkyl, which is unsubstituted or substituted with halogen,

(4) —O—C 1-6 alkyl, which is unsubstituted or substituted with halogen, and

(5) —NH—C 1-6 alkyl, or —N(C 1-6 alkyl)(C 1-6 alkyl), which is unsubstituted or substituted with halogen;

R 3 is C 1-6 alkyl;

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 of the formula Ic:

or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1 wherein R 1c is hydrogen and R 1a and R 1b are independently selected from the group consisting of:

(1) hydrogen,

(2) chloro,

(3) fluroro,

(4) methyl,

(5) triazolyl,

(6) oxazolyl,

(7) pyrimidinyl, and

(8) phenyl.

4. The compound of claim 1 wherein R 2c is hydrogen, and R 2a and R 2b are independently selected from the group consisting of:

(1) hydrogen,

(2) chloro,

(3) fluoro,

(4) bromo,

(5) methoxy,

(6) t-butoxy,

(7) difluoromethyl, and

(8) trifluoromethyl.

5. The compound of claim 1 wherein R 3 is methyl.

6. A compound which is selected from the group consisting of:

1-({6-methyl-1[2-(2H-1,2,3-triazol-2-yl)benzoyl]piperidin-3-yl}oxy)-isoquinoline;

1-({(2R,5R)-6-methyl-1-[2-(2H-1,2,3-triazol-2-yl)benzoyl]piperidin-3-yl}oxy)-isoquinoline;

1-({(2S,5R)-6-methyl-1-[2-(2H-1,2,3-triazol-2-yl)benzoyl]piperidin-3-yl}oxy)-isoquinoline;

1-({(2R,5S)-6-methyl-1-[2-(2H-1,2,3-triazol-2-yl)benzoyl]piperidin-3-yl}oxy)-isoquinoline;

1-({(2S,5R)-6-methyl-1-[2-(2H-1,2,3-triazol-2-yl)benzoyl]piperidin-3-yl}oxy)-isoquinoline;

N-{6-methyl-1-[5methyl-2(2H-1,2,3-triazol-2-yl)benzoyl]piperidin-3-yl}isoquinolin-1-amine;

N-{(2R,5R)-6-methyl-1-[5methyl-2-(2H-1,2,3-triazol-2-yl)benzoyl]piperidin-3-yl}isoquinolin-1-amine;

N-{(2S,5S)-6-methyl-1-[5methyl-2-(2H-1,2,3-triazol-2-yl)benzoyl]piperidin-3-yl}isoquinolin-1-amine;

N-{(2R,5S)-6-methyl-1-[5methyl-2-(2H-1,2,3-triazol-2-yl)benzoyl]piperidin-3-yl}isoquinolin-1-amine;

N-{(2S,5R)-6-methyl-1-[5methyl-2-(2H-1,2,3-triazol-2-yl)benzoyl]piperidin-3-yl}isoquinolin-1-amine;

8-({6-methyl-1-[2-(2H-1,2,3-triazol-2-yl)benzoyl]piperidin-3-yl}oxy)isoquinoline;

(2R,5R)-8-({6-methyl-1-[2-(2H-1,2,3-triazol-2-yl)benzoyl]piperidin-3-yl}oxy)isoquinoline;

(2S,5S)-8-({6-methyl-1-[2-(2H-1,2,3-triazol-2-yl)benzoyl]piperidin-3-yl}oxy)isoquinoline;

(2R,5S)-8-({6-methyl-1-[2-(2H-1,2,3-triazol-2-yl)benzoyl]piperidin-3-yl}oxy)isoquinoline;

(2S,5R)-8-({6-methyl-1-[2-(2H-1,2,3-triazol-2-yl)benzoyl]piperidin-3-yl}oxy)isoquinoline;

5-({6-methyl-1-[2-(2H-1,2,3-triazol-2-yl)benzoyl]piperidin-3-yl}oxy)isoquinoline;

(2R,5R)-5-({6-methyl-1-[2-(2H-1,2,3-triazol-2-yl)benzoyl]piperidin-3-yl}oxy)isoquinoline;

(2S,5S)-5-({6-methyl-1-[2-(2H-1,2,3-triazol-2-yl)benzoyl]piperidin-3-yl}oxy)isoquinoline;

(2R,5S)-5-({6-methyl-1-[2-(2H-1,2,3-triazol-2-yl)benzoyl]piperidin-3-yl}oxy)isoquinoline;

(2S,5R)-5-({6-methyl-1-[2-(2H-1,2,3-triazol-2-yl)benzoyl]piperidin-3-yl}oxy)isoquinoline;

1-chloro-4-({6-methyl-1-[2-(2H-1,2,3-triazol-2-yl)benzoyl]piperidin-3-yl}oxy)isoquinoline;

(2R,5R)-1-chloro-4-({6-methyl-1-[2(2H-1,2,3-triazol-2-yl)benzoyl]piperidin-3-yl}oxy)isoquinoline;

(2S,5S)-1-chloro-4-({6-methyl-1-[2-(2H-1,2,3-triazol-2-yl)benzoyl]piperidin-3-yl}oxy)isoquinoline;

(2R,5S)-1-chloro-4-({6-methyl-1-[2(2H- 1,2,3-triazol-2-yl)benzoyl]piperidin-3-yl}oxy)isoquinoline;

(2S,5R)-1-chloro-4-({6-methyl-1-[2-(2H- 1,2,3-triazol-2-yl)benzoyl]piperidin-3-yl}oxy)isoquinoline;

1-({6methyl-1-[2-(2H-1,2,3-triazol-2-yl)benzoyl]piperidin-3-yl}oxy)isoquinoline;

(2R,5R)-1-({6-methyl-1-[2-(2H-1,2,3-triazol-2-yl)benzoyl]piperidin-3-yl}oxy)isoquinoline;

(2S,5S)-1-({6-methyl-1-[2-(2H-1,2,3-triazol-2-yl)benzoyl]piperidin-3-yl}oxy)isoquinoline;

(2R,5S)-1-({6-methyl-1-[2-(2H-1,2,3-triazol-2-yl)benzoyl]piperidin-3-yl}oxy)isoquinoline;

(2S,5R)-1-({6-methyl-1-[2-(2H-1,2,3-triazol-2-yl)benzoyl]piperidin-3-yl}oxy)isoquinoline;

7-bromo-1-({6-methyl-1-[2-(2H-1,2,3-triazol-2-yl)benzoyl]piperidin-3-yl}oxy)isoquinoline;

(2R,5R)-7-bromo-1-({6-methyl-1-[2-(2H-1,2,3-triazol-2-yl)benzoyl]piperidin-3-yl}oxy)isoquinoline;

(2S,5S)-7-bromo-1-({6-methyl-1-[2-(2H-1,2,3-triazol-2-yl)benzoyl]piperidin-3-yl}oxy)isoquinoline;

(2R,5S)-7-bromo-1-({6-methyl-1-[2-(2H-1,2,3-triazol-2-yl)benzoyl]piperidin-3-yl}oxy)isoquinoline;

(2S,5R)-7-bromo-1-({6-methyl-1-[2-(2H-1,2,3-triazol-2-yl)benzoyl]piperidin-3-yl}oxy)isoquinoline;

4-methoxy-1-({6-methyl-1-[2-(2H-1,2,3-triazol-2-yl)benzoyl]piperidin-3-yl}oxy)isoquinoline;

(2R,5R)-4-methoxy-1-({6-methyl-1[2-(2H-1,2,3-triazol-2-yl)benzoyl]piperidin-3-yl}oxy)isoquinoline;

(2S,5S)-4-methoxy-1-({6-methyl-1-[2-(2H-1,2,3-triazol-2-yl)benzoyl]piperidin-3-yl}oxy)isoquinoline;

(2R,5S)-4-methoxy-1-({6-methyl-1-[2-(2H-1,2,3-triazol-2-yl)benzoyl]piperidin-3-yl}oxy)isoquinoline;

(2S,5R)-4-methoxy-1-({6-methyl-1-[2-(2H- 1,2,3-triazol-2-yl)benzoyl]piperidin-3-yl}oxy)isoquinoline;

1-({6-methyl-1-[methyl-2-(2H-1,2,3-triazol-2-yl)benzoyl]piperidin-3-yl}oxy)isoquinoline;

(2R,5R)-1-({6-methyl-1-[5-methyl-2-(2H-1,2,3-triazol-2-yl)benzoyl]piperidin-3-yl}oxy)isoquinoline;

(2S,5S)-1-({6-methyl-1-[5-methyl-2-(2H-1,2,3-triazol-2-yl)benzoyl]piperidin-3-yl}oxy)isoquinoline;

(2R,5S)-1-({6-methyl-1-[5-methyl-2-(2H-1,2,3-triazol-2-yl)benzoyl]piperidin-3-yl}oxy)isoquinoline;

(2S,5R)-1-({6-methyl-1-[5-methyl-2(2H- 1,2,3-triazol-2-yl)benzoyl]piperidin-3-yl}oxy)isoquinoline;

1-{[6-methyl-1-(2-pyridin-3-ylbenzoyl)piperidin-3-yl]oxy}isoquinoline;

(2R,5R)-1-{[6-methyl-1-(2-pyridin-3-ylbenzoyl)piperidin-3-yl]oxy}isoquinoline;

(2S,5S)-1-{[6-methyl-1-(2-pyridin-3-ylbenzoyl)piperidin-3-yl]oxy}isoquinoline;

(2R,5S)-1-{[6-methyl-1-(2-pyridin-3-ylbenzoyl)piperidin-3-yl]oxy}isoquinoline;

(2S,5R)-1-{[6-methyl-1-(2-pyridin-3-ylbenzoyl)piperidin-3-yl]oxy}isoquinoline;

1-{[6-methyl-1-(2-pyrimidin-2-ylbenzoyl)piperidin-3-yl]oxy}isoquinoline;

(2R,5R)-1-{[6-methyl-1-(2-pyrimidin-2-ylbenzoyl)piperidin-3-yl]oxy}isoquinoline;

(2S,5S)-1-{[6-methyl-1-(2-pyrimidin-2-ylbenzoyl)piperidin-3-yl]oxy}isoquinoline;

(2R,5S)-1-{[6-methyl-1-(2-pyrimidin-2-ylbenzoyl)piperidin-3-yl]oxy}isoquinoline;

(2S,5R)-1-{[6-methyl-1-(2-pyrimidin-2-ylbenzoyl)piperidin-3-yl]oxy}isoquinoline;

1-({6-methyl-1-[2-(1H-1,2,4-triazol-5-yl)benzoyl]piperidin-3-yl}oxy)isoquinoline;

(2R,5R)-1-({6-methyl-1-[2-(1H-1,2,4-triazol-5-yl)benzoyl]piperidin-3-yl}oxy)isoquinoline;

(2S,5S)-1-({6-methyl-1-[2-(1H-1,2,4-triazol-5-yl)benzoyl]piperidin-3-yl}oxy)isoquinoline;

(2R,5S)-1-({6-methyl-1-[2-(1H-1,2,4-triazol-5-yl)benzoyl]piperidin-3-yl}oxy)isoquinoline; and

(2S,5R)-1-({6-methyl-1-[2-(1H-1,2,4-triazol-5-yl)benzoyl]piperidin-3-yl}oxy)isoquinoline;

or a pharmaceutically acceptable salt thereof.

7. A pharmaceutical composition which comprises an inert carrier and a compound of claim 1 or a pharmaceutically acceptable salt thereof.

Assignments (4)
MERGER Recorded Aug 8, 2022
From: MERCK SHARP & DOHME CORP.
To: MERCK SHARP & DOHME LLC
Reel/Frame 061102/0145 →
CORRECTIVE ASSIGNMENT TO CORRECT THE FIRST INVENTORS NAME PREVIOUSLY RECORDED AT REEL: 032290 FRAME: 0644. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Feb 23, 2016
From: BRESLIN, MICHAEL J.; COLEMAN, PAUL J.; COX, CHRISTOPHER D.; RAHEEM, IZZAT T.; ROECKER, ANTHONY J.; SCHREIER, JOHN D.
To: MERCK SHARP & DOHME CORP.
Reel/Frame 037893/0779 →
CHANGE OF NAME Recorded Feb 25, 2014
From: MERCK & CO., INC.
To: MERCK SHARP & DOHME CORP.
Reel/Frame 032290/0511 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 25, 2014
From: B RELIN, MICHAEL J.; COLEMAN, PAUL J.; COX, CHRISTOPHER D.; RAHEEM, IZZAT T.; ROECKER, ANTHONY J.; SCHREIER, JOHN D.
To: MERCK SHARP & DOHME CORP.
Reel/Frame 032290/0644 →